Top Section/Ad
Top Section/Ad
Most recent
◆ Praemia refis at a tighter coupon ◆ Schneider lands tight at the short end ◆ Minimal concessions needed
French biotech seeks to accelerate cancer vaccine program
◆ Single digit premiums offered ◆ Reverse Yankees dominating euro supply ◆ Floaters proving popular with multi-tranche issuers
Pair enjoyed strong execution and tight pricing as US high grade credit remained resilient in the face of a sell-off in equity markets
More articles/Ad
More articles/Ad
More articles
-
Autolus Therapeutics, the UK biopharmaceutical company focused on T cell therapies for cancer, is raising additional capital on the Nasdaq. -
The Ivory Coast sought to raise some extra euro cash by tapping bonds in euros on Monday but, with two African sovereigns requesting debt restructuring support from the G20 over the last week, some market participants have begun to question the continent's borrowers.
-
Zambia, which months ago became Africa’s first sovereign default since the pandemic started, has requested debt treatment under the G20’s Common Framework. That makes it the third African sovereign to request restructuring support under the guidelines, which were first announced in November.
-
Huge demand for exposure to biotech companies among US equity investors is continuing to drive UK firms to list on the other side of the Atlantic through an IPO on the Nasdaq. On Thursday, Immunocore, a late-stage biotech firm focused on T-cell technology, priced an enlarged offering on the exchange and, on Friday, UK healthcare investor Syncona announced it was exploring a US IPO for one of its portfolio companies.
-
Medical device manufacturer New Horizon Health has pulled in early demand to cover its Hong Kong IPO multiple times over, according to a source familiar with the matter.
-
Cloopen Group Holding, a cloud-based communications provider, launched its New York Stock Exchange IPO on Wednesday night.
